Literature DB >> 7198937

Effective control of cisplatin-induced nausea using high-dose steroids and droperidol.

B A Mason, J Dambra, B Grossman, R B Catalano.   

Abstract

Seventy-three consecutive patients receiving cisplatin-containing chemotherapy regimens were treated with an initial dose of chlorpromazine (25 mg im), droperidol (1 mg iv, then 1 mg sc every 4 hours), and methylprednisolone (250 mg every 4 hours for four doses). Twenty patients received a combination chemotherapy protocol that included cisplatin at a dose of 40 mg/m2 iv (group 1) and 53 patients received a protocol that included cisplatin at a dose of 120 mg/m2 iv (group 2). The median age of all the patients was 58 years. Seventy-five percent of the patients in group 1 and 45% of those in group 2 had no vomiting at all; the remainder had limited and tolerable vomiting. These results in a group of elderly patients compare favorably with trials of other antiemetic programs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7198937

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  8 in total

1.  Antiemetic activity of high-dose methylprednisolone associated with continuous-infusion metoclopramide and oral alprazolam during multiple-day chemotherapy.

Authors:  G Salles; E Archimbaud; X Thomas; D Fiere
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  High-dose corticosteroids for the management of dyspnea in patients with tumor obstruction of the upper airway.

Authors:  Ahmed Elsayem; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2007-07-17       Impact factor: 3.603

3.  Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings.

Authors:  Lorenzo Cohen; Carl A de Moor; Peter Eisenberg; Eileen E Ming; Henry Hu
Journal:  Support Care Cancer       Date:  2006-11-14       Impact factor: 3.603

4.  Continuous infusion of high-dose metoclopramide for the prevention of nausea and vomiting in patients receiving cancer chemotherapy.

Authors:  R A Joss; R L Galeazzi; K W Brunner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].

Authors:  A Du Bois
Journal:  Med Klin (Munich)       Date:  1998-01

6.  Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose i.v. metoclopramide and high-dose i.v. dexamethasone.

Authors:  S Frustaci; E Grattoni; S Tumolo; D Crivellari; F Figoli; E Galligioni; A Veronesi; U Tirelli; E Grigoletto
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with a combination of dexamethasone, metoclopramide and diphenhydramine.

Authors:  H Y al-Idrissi; E M Ibrahim; K A Abdullah; W A Ababtain; H A Boukhary; H M Macaulay
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

8.  A research study review of effectiveness of treatments for psychiatric conditions common to end-stage cancer patients: needs assessment for future research and an impassioned plea.

Authors:  Ralph J Johnson
Journal:  BMC Psychiatry       Date:  2018-04-03       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.